## Journal Pre-Proof

Total synthesis of Punicagranine

Charles K. Perry, Craig W. Lindsley

 PII:
 \$0040-4039(19)30744-0

 DOI:
 https://doi.org/10.1016/j.tetlet.2019.150989

 Reference:
 TETL 150989

To appear in: Tetrahedron Letters

Received Date:11 July 2019Revised Date:16 July 2019Accepted Date:26 July 2019



Please cite this article as: Perry, C.K., Lindsley, C.W., Total synthesis of Punicagranine, *Tetrahedron Letters* (2019), doi: https://doi.org/10.1016/j.tetlet.2019.150989

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier Ltd.

## **Graphical Abstract**

To create your abstract, type over the instructions in the template box below. Fonts or abstract dimensions should not be changed or altered.





Tetrahedron Letters journal homepage: www.elsevier.com

# **Total synthesis of Punicagranine**

Charles K. Perry<sup>‡</sup> and Craig W. Lindsley<sup>¥,‡</sup>\*

\*Department of Chemistry, Department of Biochemistry, Vanderbilt University, Nashville, TN 37232-6600, U.S.A. \*Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232-6600, U.S.A

#### ARTICLE INFO

ABSTRACT

Article history: Received Received in revised form Accepted Available online

*Keywords:* Punicagranine total synthesis 1,3-dipolar cycloaddition pyrrolizine This communication details the first total synthesis of Punicagranine, a new pyrrolizine alkaloid isolated from the peels of the pomengranate, *Punica granatum*, the basis for traditional Chinese medicine, with anti-inflammatory activity. Two concise, 4-5 step routes were developed to rapidly prepare Punicagranine in 10.7 to 12.1% overall yields. One route features an intramolecular Heck reaction, while the other relies on a 1,3-dipolar cycloaddition. The latter route proceeds on scale to support future biological studies.

2019 Elsevier Ltd. All rights reserved.

The peels of the pomegranate, *Punica granatum*, have been used in traditional Chinese medicine as an anti-inflammatory agent to treat a number of diseases, as well as possessing significant anticancer activities.<sup>1-5</sup> The report in 2019 by Du and Sun describing the isolation and identification of a novel pyrrolizine alkaloid, punicagranine (1) from the peels of *Punica granatum* with anti-inflammatory activity attracted our attention, as 1 represents an active component (**Figure 1**).<sup>6</sup> Moreover, the novel structure, drug-like features and potential for the generation of active metabolites (due to the furanyl ketone moiety) *in vivo* argued well for the synthesis of 1 and further biological evaluation.



**Figure 1.** Structure of punicagranine (1) and the numbering convention (inset). This unique skeleton has never before been reported in nature. The structure of 1 was determined by 1D- and 2D-NMR, and confirmed by single X-ray crystal structure.

We envisioned two distinct retrosynthetic approaches to access 1, employing fundamentally distinct strategies as depicted in Figure 2, yet both requiring only four linear steps. Key bond disconnections in route A lead to intermediate 2, which can be assembled through a 1,3-dipolar cycloaddition reaction with

readily available/commercial materials **3** and **4**. Route B, in contrast disconnects the pyrrolidine ring juncture, **5**, which could be assembled via an intramolecular Heck reaction. An *N*-alkylation and Friedel-Crafts reaction sequence leads to commercial starting materials **6** and **7**.



Figure 2. Retrosynthesis of 1. Route A, features a final Friedel-Crafts acylation on the core 2, which can be derived *N*-formyl protected D,L-proline 3 and methyl propiolate 4. In Contrast, Route B features a final intramolecular Heck reaction to assemble the pyrrolidine ring from 5, which can be assembled via alkylation and an initial Friedel-Crafts acylation, leading to 6 and 7.

1

Route A was based on the work of Albonico,<sup>7</sup> wherein a 5,6 homologated congener of **2**, a 5,6,7,8-tetrahydroindolizine **9**, was prepared in 82% yield via a cycloaddition of methyl propiolate **4** and *N*-formyl-2-piperidine carboxylic acid **8** through a 1,3-dipolar intermediate (**Figure 3**). This approach had not been applied to 5,5-systems, such as the requisite methyl 2,3-dihydro-1H-pyrrolizine-7-carboxylate **2**.



Figure 3. Albonico's 1.3-dipolar cycloaddition strategy to access a 5,6,7,8-tetrahydroindolizine 8.

Thus, we found this attractive and elected to evaluate if this cycloaddition methodology would extend to a 5,5-system **2**. In the event, commercial D,L-proline **10** was converted to the *N*-formyl derivative **3** in quantitative yield (**Scheme 1**).<sup>8</sup> Following the literature conditions,<sup>7</sup> the reaction was sluggish, with little conversion after two hours. Extending the reaction time to 16 hours delivered the desired methyl 2,3-dihydro-1*H*-pyrrolizine-7-carboxylate **2** in a modest, unoptimized 39% yield. With **2** in hand, a Friedel-Crafts reaction with furan-2-carbonyl chloride **7** provided **11**. Finally, saponification of **11** under standard conditions gave punicagranine (**1**) in 87% yield. Overall, this route required only four steps and 12.1% overall yield; moreover, our synthetic **1** was in complete agreement with that of the natural product.<sup>6,8</sup>



Scheme 1. Route A Synthesis of 1. Reagents and conditions: (a)  $CH_2O_2$ ,  $Ac_2O$ , rt, 1 h, 99%; (b) methyl propiolate (4),  $Ac_2O$ , 120 °C, 16h, 39%; (c) furan-2-carbonyl chloride (7),  $AlCl_3$ ,  $ClCH_2CH_2Cl$ , rt, 2h, 36%; (d) 2 N NaOH, EtOH, 60 °C, 1h, 87%.

In parallel, we also pursued alternative Route B (Scheme 2). Here, methyl 1*H*-pyrrole-3-carboxylate 6 undergoes a Friedel-Crafts reaction with 7 to provide the disubstituted pyrrole 12 in 63% yield. Alkylation of the pyrrole with 1,3-dibromopropane proceeded smoothly, followed by a Finkelstein reaction generating the alkyl iodide 5 which set the stage for an intramolecular Heck reaction. In this case, the intramolecular Heck reaction required forcing conditions<sup>9</sup> (i.e., refluxing *tert*-butylbenzene for 16 hours), but proceeded in 40% yield to deliver 11. As in Route A, saponification of 11 under standard

conditions gave punicagranine (1) in 87% yield. Overall, this route required only five steps from commercial materials and 10.7% overall yield; moreover, our synthetic 1 was in complete agreement with that of the natural product.<sup>6,8</sup>



Scheme 2. Route B Synthesis of 1. Reagents and conditions: (a) furan-2carbonyl chloride (7), AlCl<sub>3</sub>, ClCH<sub>2</sub>CH<sub>2</sub>Cl, rt, 2h, 63%; (b) i) 1,3dibromoethane, KOH, DMF, rt, 16h, 57%; ii) NaI, acetone, 60 °C, 1.5 h, 86%; (c) 10 mol % Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, *tert*-butylbenzene, 130 °C, 16 h, 40%; (d) 2 N NaOH, EtOH, 60 °C, 1h, 87%.

In conclusion, we have presented the first total synthesis of punicagranine (1) utilizing two distinct routes that require only four to five steps from commercial materials and proceed in 10.7-12.1% overall yields. In addition, our modular synthetic approach enables facile analog development, which will prove useful for the future exploration of anti-inflammatory SAR around related congeners, as well as target identification and metabolite identification studies.

#### Acknowledgments

Financial support from the Warren Family and Foundation is gratefully acknowledged and for establishing the William K. Warren, Jr. Chair in Medicine.

#### **References and notes**

- [1] E. Shaygannia, M. Bahmani, B. Zamanzad, et al., J. Evid. Based Complementary Altern. Med. 21 (2016) 221–227.
- [2] National Pharmacopoeia Committee, Pharmacopoeia of People's Republic of China, Part 1, Chemical Industry Press, Beijing, 2010, p. 87.
- [3] S. Modaeinama, M. Abasi, M.M. Abbasi, et al., Asian Pac. J. Cancer Prev. 16 (2015) 5697–5701.
- [4] E.P. Lansky, R.A. Newman, J. Ethnopharmacol. 109 (2007) 177–206.
- [5] G.W. Plumb, S. De Pascual-Teresa, C. Santos-Buelga, J.C. Rivas-Gonzalo, G. Williamson, Redox Rep. 41 (2002) 41–46.
- [6] H-y. Sun, N. Ma. T. Pan, et al., Tetrahedron Lett. 60 (2019) 1231-1233.
- [7] M.T. Pizzorno, S.M. Albonico J. Org. Chem. 42 (1977) 909-910.
- [8] See Supporting Information for full details.
- [9] R.O. Alexander, P.T. Bohan, E.J. Alexanian J. Am. Chem. Soc. 137 (2015) 3731-3734.

### Appendix A. Supplementary data

The following are the Supplementary data to this article:

### **AUTHOR INFORMATION**

Corresponding Author \* E-mail: <u>craig.lindsley@vanderbilt.edu</u> Phone: 615-322-8700, fax: 615-343-3088

- First total synthesis of punicagranine
- Two distinct routes, only 4-5 steps and >10% overall yields
- Sufficient material to support mechanism of action studies